210 related articles for article (PubMed ID: 7051411)
1. Thromboxane synthetase inhibition results in increased platelet sensitivity to prostacyclin.
Bertelé V; Falanga A; Roncaglioni MC; Cerletti C; de Gaetano G
Thromb Haemost; 1982 Jun; 47(3):294. PubMed ID: 7051411
[No Abstract] [Full Text] [Related]
2. Modulation of human platelet function by prostacyclin and thromboxane A2.
Gorman RR
Fed Proc; 1979 Jan; 38(1):83-8. PubMed ID: 215465
[No Abstract] [Full Text] [Related]
3. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
Bertele V; De Gaetano G
Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787
[TBL] [Abstract][Full Text] [Related]
4. The generation of TXA2 in human platelet rich plasma and its inhibition by nictindole and prostacyclin.
Grodzińska L; Marcinkiewicz E
Pharmacol Res Commun; 1979 Feb; 11(2):133-46. PubMed ID: 375247
[No Abstract] [Full Text] [Related]
5. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.
Aiken JW; Shebuski RJ; Miller OV; Gorman RR
J Pharmacol Exp Ther; 1981 Nov; 219(2):299-308. PubMed ID: 6270303
[No Abstract] [Full Text] [Related]
6. A biphasic effect of prostacyclin (PGI2) on platelet aggregation.
Jørgensen KA; Dyerberg J; Stoffersen E
Thromb Res; 1980 Sep; 19(6):877-81. PubMed ID: 6258262
[No Abstract] [Full Text] [Related]
7. [Suppression of platelet aggregation as a result of two-component inhibition of a polyenzyme system of thromboxane synthesis].
Varfolomeev SD; Lakin KM; Mevkh AT; Novikova NV; Rukazenkov IuZ
Dokl Akad Nauk SSSR; 1985; 282(1):194-6. PubMed ID: 3928305
[No Abstract] [Full Text] [Related]
8. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.
FitzGerald GA; Brash AR; Oates JA; Pedersen AK
J Clin Invest; 1983 Oct; 72(4):1336-43. PubMed ID: 6355181
[TBL] [Abstract][Full Text] [Related]
9. Biology and biochemistry of thromboxane synthetase inhibitors.
Gorman RR
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():235-40. PubMed ID: 6221529
[No Abstract] [Full Text] [Related]
10. Inhibition of arachidonate-induced human platelet aggregation by a single low oral dose of aspirin in combination with a thromboxane synthase inhibitor.
Cerletti C; Rajtar G; Bertelé V; de Gaetano G
Thromb Haemost; 1984 Oct; 52(2):215. PubMed ID: 6441306
[No Abstract] [Full Text] [Related]
11. Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation.
Bartele V; Cerletti C; Schiepatti A; di Minno G; de Gaetano G
Lancet; 1981 May; 1(8228):1057-8. PubMed ID: 6112437
[No Abstract] [Full Text] [Related]
12. Amelioration of the deleterious effects of platelets activated during cardiopulmonary bypass. Comparison of a thromboxane synthetase inhibitor and a prostacyclin analogue.
Huddleston CB; Hammon JW; Wareing TH; Lupinetti FM; Clanton JA; Collins JC; Bender HW
J Thorac Cardiovasc Surg; 1985 Feb; 89(2):190-5. PubMed ID: 2578591
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of platelet aggregation by 1-alkylimidazole derivatives, thromboxane A synthetase inhibitors.
Kayama N; Sakaguchi K; Kaneko S; Kubota T; Fukuzawa T; Kawamura S; Yoshimoto T; Yamamoto S
Prostaglandins; 1981 Apr; 21(4):543-54. PubMed ID: 7196056
[TBL] [Abstract][Full Text] [Related]
14. Different effects of thromboxane synthetase inhibitors on platelets from different individuals.
Lancet; 1982 Nov; 2(8308):1156-7. PubMed ID: 6128469
[No Abstract] [Full Text] [Related]
15. Effect of the thromboxane synthetase inhibitor Dazoxiben (UK 37-248) on the metabolism of antipyrine in patients with enhanced platelet aggregation.
Staiger C; Walter E; Wang NS; Schuhmacher E; de Vries J; Weber E
Int J Clin Pharmacol Ther Toxicol; 1984 May; 22(5):250-3. PubMed ID: 6540249
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of thromboxane synthetase by dazoxiben increases prostacyclin production by leukocytes in angina patients and healthy volunteers.
Parry MJ; Randall MJ; Tyler HM; Myhre E; Dale J; Thaulow E
Lancet; 1982 Jul; 2(8290):164. PubMed ID: 6123880
[No Abstract] [Full Text] [Related]
17. Thromboxane synthetase inhibitors as pharmacological tools: differential biochemical and biological effects on platelet suspensions.
Needleman P; Bryan B; Wyche A; Bronson SD; Eakins K; Ferrendelli JA; Minkes M
Prostaglandins; 1977 Nov; 14(5):897-907. PubMed ID: 594391
[TBL] [Abstract][Full Text] [Related]
18. Thromboxane synthase inhibition in patients with atherosclerotic heart disease.
Knudsen JB; Juhl A; Gormsen J
Lancet; 1981 Jul; 2(8239):198. PubMed ID: 6114260
[No Abstract] [Full Text] [Related]
19. Inhibition of human platelet thromboxane synthetase by 9,11-azoprosta-5,13-dienoic acid.
Gorman RR; Bundy GL; Peterson DC; Sun FF; Miller OV; Fitzpatrick FA
Proc Natl Acad Sci U S A; 1977 Sep; 74(9):4007-11. PubMed ID: 269449
[TBL] [Abstract][Full Text] [Related]
20. Platelet thromboxane synthetase inhibitors with low doses of aspirin: possible resolution of the "aspirin dilemma".
Bertelé V; Falanga A; Tomasiak M; Dejana E; Cerletti C; de Gaetano G
Science; 1983 Apr; 220(4596):517-9. PubMed ID: 6682245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]